CSL (ASX:CSL) has reported its net profit after tax (NPAT) rose about 28 per cent on FY17 to $1.7 billion for the 2018 financial year.
CSL’s profit result was in line with UBS expectations.
In more good news for the biotech company, its revenue strengthened over the 2018 financial year, and lifted 11 per cent on FY16 to $7.9 billion.
Its earnings before interest and tax (EBIT) increased over 33 per cent on the prior year, to around $2.4 billion.
The company declared a total full year dividends of $1.72 per share a rise of 26 per cent on last year.
CSl says net profit for the 2019 financial year is expected to be in the range of $1.88 to $1.95 billion a rise of 10 14 per cent on this year’s result.
Shares in CSL (ASX:CSL) is trading 0.52 per cent higher to $202.74.